Squarepoint’s Procept Biorobotics PRCT Stock Holding History

Squarepoint’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,500	Closed	-$339K	–	4741
2025 Q3	$339K	Buy	+9,500	New	+$434K	﹤0.01%	3573
2025 Q1	–	Sell	-5,100	Closed	-$411K	–	5229
2024 Q4	$411K	Buy	+5,100	New	+$436K	﹤0.01%	3907
2024 Q3	–	Sell	-23,700	Closed	-$1.45M	–	4569
2024 Q2	$1.45M	Sell	23,700 -300	-1%	-$17.8K	﹤0.01%	2291
2024 Q1	$1.19M	Hold	24,000	–	–	﹤0.01%	2470
2023 Q4	$1.01M	Buy	+24,000	New	+$817K	﹤0.01%	2517

Other funds holding PRCT

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Champlain Investment Partners Burlington, Vermont $2.9B AUM 23.58% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Rhenman & Partners Asset Management Stockholm, Sweden $903M AUM 49.67% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Squarepoint's PRCT Position: Q3 2026 in Review

Squarepoint increased its Procept Biorobotics (PRCT) stake by 54% in Q3 2026, buying an estimated $287K and bringing the position to 40,816 shares worth $744K. The position accounts for ﹤0.01% of the portfolio, ranked #3044.

Squarepoint first reported a position in PRCT in Q3 2021 and has held it in 14 quarters since. The position peaked at $12.9M in Q1 2025. 137 funds tracked by Wall St. Rank hold PRCT as of Q3 2026.

Squarepoint held 40,816 shares of Procept Biorobotics worth $744K as of Q3 2026.
Squarepoint bought 14,386 Procept Biorobotics shares in Q3 2026, an estimated $287K.
Procept Biorobotics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #3044 holding.
Squarepoint first reported a position in Procept Biorobotics in Q3 2021 and has held it in 14 quarters since.
Squarepoint's Procept Biorobotics position peaked at $12.9M in Q1 2025.
137 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.